Few studies explored the role of microRNAs (miRNAs) in the post‐transcriptional regulation of glycolytic proteins and downstream effectors in ovarian cancer cells. We recently showed that the functional activation of the cytoskeletal regulator FAK in endothelial cells is fostered by the glycolytic enhancer 6‐phosphofructo‐2‐kinase/fructose‐2,6‐biphosphatase 3 (PFKFB3). We tested the hypothesis that miR‐206 and mir‐26b, emerging onco‐suppressors targeting PFKFB3 in estrogen‐dependent tumors, would regulate proliferation and migration of serous epithelial ovarian cancer (EOC) cells via common glycolytic proteins, i.e., GLUT1 and PFKFB3, and downstream FAK. PFKFB3 was overexpressed in SKOV3, and its pharmacological inhibition with 3‐(3‐pyridinyl)‐1‐(4‐pyridinyl)‐2‐propen‐1‐one (3PO) significantly reduced cell proliferation and motility. Both miR‐206 and miR‐26b directly targeted PFKFB3 as evaluated by a luciferase reporter assay. However, endogenous levels of miR‐26b were higher than those of miR‐206, which was barely detectable in SKOV3 as well as OVCAR5 and CAOV3 cells. Accordingly, only the anti‐miR‐26b inhibitor concentration‐dependently increased PFKFB3 levels. While miR‐206 overexpression impaired proliferation and migration by downregulating PFKFB3 levels, the decreased PFKFB3 protein levels related to miR‐26 overexpression had no functional consequences in all EOC cell lines. Finally, consistent with the migration outcome, exogenous miR‐206 and miR‐26b induced opposite effects on the levels of total FAK and of its phosphorylated form at Tyr576/577. 3PO did not prevent miR‐26b‐induced SKOV3 migration. Overall, these results support the inverse relation between endogenous miRNA levels and their tumor‐suppressive effects and suggest that restoring miR‐206 expression represents a potential dual anti‐PFKFB3/FAK strategy to control ovarian cancer progression.